Specialty code 183500000X · Roseville, CA
NPI
1386071405
Since 2013
Specialty
Specialty code 183500000X
Code 183500000X
Group practices
0
Medicare group memberships
Hospitals
0
Hospital affiliations
1600 Eureka Rd
Roseville, CA, 95661
Phone (916) 784-4184
Medicare paid
-
No Medicare services published
Medicare patients
-
Drug cost, 2024
$316K
3,196 prescriptions
Company payments
-
None reported
Medicare prescription drug claims, 2024
In 2024, the drug Derren Cheongsiatmoy prescribed most often to Medicare patients was Atorvastatin Calcium, with 620 prescriptions and refills. In total Derren Cheongsiatmoy wrote 3,196 Medicare prescriptions that cost $316K.
| Drug |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-11-26.
| Claims |
|---|
| 30-day fills |
|---|
| Patients |
|---|
| Cost |
|---|
| Atorvastatin Calcium Generic | 620 | 2,061 | 225 | $7,656 |
| Metformin Hcl Er Metformin Hcl | 394 | 1,305 | 158 | $3,979 |
| Glipizide Generic | 240 | 797 | 93 | $3,629 |
| Jardiance Empagliflozin | 239 | 795 | 95 | $155K |
| Metformin Hcl Generic | 144 | 475 | 57 | $1,868 |
| Amlodipine Besylate Generic | 128 | 427 | 46 | $1,533 |
| Losartan Potassium Generic | 113 | 377 | 41 | $1,412 |
| Lisinopril Generic | 112 | 373 | 39 | $1,327 |
| Insulin Glargine-Yfgn Generic | 107 | 304 | 49 | $13K |
| Humulin N Insulin Nph Human Isophane | 100 | 307 | 47 | $19K |
| Veo Insulin Syringe Syringe-Needle,insulin,0.5 Ml | 99 | 302 | 48 | $2,972 |
| Glimepiride Generic | 97 | 314 | 41 | $1,339 |
| Simvastatin Generic | 79 | 263 | 28 | $922 |
| Hydrochlorothiazide Generic | 78 | 260 | 27 | $910 |
| Humulin R Insulin Regular, Human | 61 | 184 | 28 | $12K |
Brand drugs: 686 claims; generic drugs: 2,294 claims.
Money and other things of value reported by the companies
No payments from drug or medical device companies to Derren Cheongsiatmoy were reported in the years we have.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.